Skip to content

Clinical trials

Phase 3 Metabolic Diseases trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Metabolic Diseases Phase: Phase 3 Country / region: United States Clear all

41 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20072
20082
20096
20104
20121
20141
20152
20162
20171
20181
20201
20226
20232
20247
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed23
Active, not recruiting8
Terminated6
Recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca6
Eli Lilly and Company6
89bio, Inc.3
Regeneron Pharmaceuticals3
Agios Pharmaceuticals, Inc.2
Amgen2
Kastle Therapeutics, LLC2
Otsuka Pharmaceutical Development & Commercialization, Inc.2
Pfizer2
Ultragenyx Pharmaceutical Inc2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Metabolic Diseases41
Glucose Metabolism Disorders17
Diabetes Mellitus, Type 216
Diabetes Mellitus15
Endocrine System Diseases15
Genetic Diseases, Inborn8
Metabolism, Inborn Errors7
Dyslipidemias5
Hyperlipidemias5
Lipid Metabolism Disorders5

Trials

Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.